TWST at a glance
Twist Bioscience Corp (TWST, SEC CIK 1581280) filed its latest 10-K annual report on November 16, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended September 30, 2026 (FY2026), Twist Bioscience Corp (TWST) reported revenue of $459.4 million (up 22.0% from FY2025) and a net loss of $130.2 million. Diluted EPS was -$2.08.
- As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Twist Bioscience Corp (TWST) shares worth $7.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by WERNER ROBERT F. on November 16, 2026 of 1,637 shares at $103.69 per share.
- In the last 90 days, TWST insiders reported 0 open-market purchases ($0) and 65 open-market sales ($91.7M) on Form 4, a net sale of $91.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $459.4M
- +22.0% vs prior year
- Insiders · 90 days
- 0 buys · 65 sells
- Net −$91.7M
- 13F holders
- 32 funds
- $7.1B · −1 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Sep 30, 2026
Business Overview
- Silicon-based DNA synthesis platform: customizable DNA, proteins and sequencing workflow solutions across life sciences markets
- Fiscal 2026 segment reorganization: combined synthetic biology and antibody discovery into DNA Synthesis and Protein Solutions
- AI drug discovery emphasis: Twist became a protein and data partner, with substantially increased customer demand
- February 2026 bispecific expansion: co-exclusive Invenra B-Body license and minority equity investment
- Revenue $459.4 million from approximately 4,100 customers, with 1,080 employees as of September 30, 2026
Management Discussion & Analysis
- Revenue $459.4M, up 22% YoY from $376.6M, driven by DNA Synthesis and Protein Solutions and NGS Applications
- Gross margin 52.4% vs 50.7%; operating loss $139.5M vs $136.3M
- Best segment DNA Synthesis and Protein Solutions, revenue $221.9M, up $53.4M; weakest growth NGS Applications, revenue $237.5M, up $29.4M
- Operating cash use $41.4M; capex $47.6M; financing cash $446.7M, including $327.7M offering proceeds and $97.1M ATM proceeds
- Outlook: AI-enabled drug discovery demand expected to grow in fiscal 2027; approximately $150M capex planned over two years, with reimbursement and regulatory risks
Risk Factors
- Biosecurity regulation: Executive Order 14292 and proposed H.R. 3029 could increase nucleic-acid screening costs, turnaround times, and fulfillment constraints
- Geopolitical exposure: International customers generated 41% of fiscal 2026 revenue amid tariffs, Russia-China tensions, and Israel-Hamas conflict
- Supply-chain vulnerability: One single-source supplier provides a critical DNA-synthesis component Twist cannot manufacture internally
- Competitive disruption: Integrated DNA Technologies, GenScript, and emerging silicon-chip technologies threaten Twist’s platform advantage
- Financial risk: Net loss $130.2 million and accumulated deficit $1,449.8 million as of September 30, 2026, with potential further equity dilution
AI summary of the TWST 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $118.4M, up 23% YoY from $96.1M, led by DNA synthesis and protein solutions growth of 39%
- Gross margin 52.8% vs 53.4% YoY, primarily due to customer mix
- NGS applications largest product line at $61.8M, 52% of quarterly revenue; DNA synthesis and protein solutions $56.6M
- Cash and short-term investments $166.8M; nine-month operating cash use $41.3M vs $35.8M
- Outlook: SG&A expected to moderate in Q4 fiscal 2026; liquidity sufficient for more than 12 months, with $200.0M ATM capacity unused
Risk Factors
- No risk-factors section provided; supplied text contains Items 2–6 and signatures only
- Insider selling risk: CEO trading plan covering approximately 624,134 shares
- Insider selling risk: COO trading plan covering up to 78,355 shares
- Insider selling risk: Director trading plan covering up to 18,417 shares
- Financing risk: June 18, 2026 sales agreement with TD Securities (USA) LLC
AI summary of the TWST 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release announces Twist Bioscience results for quarter and fiscal year ended September 30, 2026
- Full financial results and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Fiscal 2026 revenue $459.4M, up 22%, with DSPS up 31.7% and NGS up 14.1%
- Q4 revenue $126.6M, up 28%, marking the 15th consecutive quarter of sequential growth
Item 7.01: Regulation FD Disclosure
- Anthropic selected Twist as an independent evaluator for AI-designed protein production and binding tests
- Campaign spans 15 protein targets using Claude Opus 4.8 and Mythos Preview
Item 8.01: Other Events
- Twist filing prospectus supplement registering Invenra’s resale of shares issuable under February 11, 2026 Stock Purchase Agreement
- Potential increase in tradable shares and resale-related dilution overhang for existing shareholders
AI summaries of TWST 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TWST
Don't miss the next TWST filing
- Alerts as it files. A push when TWST files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TWST, by share count.
- Ask anything. An AI agent that reads every TWST filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Finn Patrick John | A | Nov 16, 2026 | 18,206 | - |
| WERNER ROBERT F. | Sell | Nov 16, 2026 | 1,637 | $103.69 |
| Finn Patrick John | Sell | Nov 16, 2026 | 12,752 | $103.69 |
| Leproust Emily M. | A | Nov 16, 2026 | 36,413 | - |
| Green Paula | Sell | Nov 16, 2026 | 4,281 | $103.69 |
| Green Paula | A | Nov 16, 2026 | 6,372 | - |
| Cho Dennis | Sell | Nov 16, 2026 | 5,427 | $103.69 |
| Cho Dennis | A | Nov 16, 2026 | 7,045 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $376.6M | $459.4M |
| Operating Income | - | -$136.3M | -$139.5M |
| Net Income | -$208.7M | -$77.7M | -$130.2M |
| Op. Margin | - | -36.2% | -30.4% |
| Net Margin | - | -20.6% | -28.3% |
| Balance Sheet | |||
| Total Assets | $614.3M | $641.9M | $1.1B |
| Equity | - | $473.0M | $888.0M |
| ROE | - | -16.4% | -14.7% |
| Per Share | |||
| EPS | $-3.60 | $-1.30 | $-2.08 |
| Cash Flow | |||
| Operating CF | - | -$47.6M | -$41.4M |
| CapEx | $5.1M | $28.0M | $47.6M |
Source: XBRL data in Twist Bioscience Corp (TWST)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate TWST share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 32 | $7.13B |
| Q2 2026 | 33 | $3.89B |
| Q1 2026 | 31 | $1.52B |
| Q4 2025 | 24 | $992.2M |
| Q3 2025 | 26 | $958.5M |
| Q2 2025 | 28 | $1.23B |
| Q1 2025 | 28 | $1.04B |
| Q4 2024 | 24 | $1.11B |
- T. Rowe Price Group+2.45M (+67%)
- JPMorgan Chase & Co+815.8K (+397%)
- D.E. Shaw & Co+640.7K (+54%)
- BlackRock+552.2K (+9%)
- Franklin Resources+448.4K (+872%)
- ARK Investment Management−1.15M (-25%)
- Dimensional Fund Advisors−346.3K (-59%)
- State Street Corp−215.5K (-7%)
- Morgan Stanley−173.6K (-15%)
- Invesco Ltd−106.3K (-6%)
- StoneX Group Inc.+1.9K
- FMR LLC (Fidelity)−4.70M
- Citadel Advisors LLC−862.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 226 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TWST filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 10-K | Nov 16, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Oct 27, 2026 | - | - | - |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
TWST SEC filings: frequently asked questions
Are TWST insiders buying or selling?
In the last 90 days, Twist Bioscience Corp (TWST) officers, directors and 10% owners reported no open-market purchases and 65 open-market sales worth $91.7 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TWST stock?
As of September 30, 2026, the largest Twist Bioscience Corp (TWST) holders among the 13F filers tracked by SignalX were BlackRock ($1.2 billion), T. Rowe Price Group ($1.2 billion), ARK Investment Management ($656.6 million), Vanguard Portfolio Management LLC ($603.4 million), State Street Corp ($583.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TWST's revenue in fiscal year 2026?
For the fiscal year ended September 30, 2026 (FY2026), Twist Bioscience Corp (TWST) reported revenue of $459.4 million (up 22.0% from FY2025) and a net loss of $130.2 million. Diluted EPS was -$2.08. The figures come from the XBRL data in the 10-K.
What are the main risks in TWST's latest 10-K?
In the 10-K filed November 16, 2026, Twist Bioscience Corp (TWST) flagged: Biosecurity regulation: Executive Order 14292 and proposed H.R. 3029 could increase nucleic-acid screening costs, turnaround times, and fulfillment constraints. Geopolitical exposure: International customers generated 41% of fiscal 2026 revenue amid tariffs, Russia-China tensions, and Israel-Hamas conflict. (AI summary of the Risk Factors section.)
What did TWST report in its latest 8-K?
Twist Bioscience Corp (TWST) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Twist Bioscience results for quarter and fiscal year ended September 30, 2026.
What are the latest TWST SEC filings?
Twist Bioscience Corp (TWST) filed its latest 10-K annual report on November 16, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 18, 2026.
What is TWST's SEC CIK number?
Twist Bioscience Corp (TWST)'s SEC Central Index Key (CIK) is 1581280. EDGAR lists every TWST filing under that number.
Ask anything about TWST
The research agent reads TWST's filings, financials, insider trades and 13F holders, then answers with sources.